肌浸润性膀胱癌新辅助化疗敏感标志物的研究进展

Q4 Medicine

中华泌尿外科杂志 Pub Date : 2020-01-15 DOI:10.3760/CMA.J.ISSN.1000-6702.2020.01.017

Zhilong Hu, Hongsong Bai

{"title":"肌浸润性膀胱癌新辅助化疗敏感标志物的研究进展","authors":"Zhilong Hu, Hongsong Bai","doi":"10.3760/CMA.J.ISSN.1000-6702.2020.01.017","DOIUrl":null,"url":null,"abstract":"Bladder cancer is one of the tenth most common malignant tumors in Chinese men. Almost 20% to 30% patients are diagnosed as the muscle-invasive bladder cancer (MIBC) at the first diagnosis.In the past, radical cystectomy (RC) was the first-line treatment with MIBC.The current researches' results show that, neoadjuvant chemotherapy combined with RC can improve the tumor complete response rate and prolong the overall survival of patients with MIBC, comparing with the RC alone. It has become the recommended standard first line treatment for MIBC, which has the possiblity of preserving bladder. Lots of researches indicate that the application of cisplatin-based neoadjuvant chemotherapy in patients with MIBC is becoming more and more popular. However, there is still the possibility of ineffectiveness or tumor progression. Therefore, discussions about the sensitivity of neoadjuvant chemotherapy have always been a hot spot in urological tumor research. In order to provide guidance and help for clinical work, the article reviews the sensitivity of neoadjuvant chemotherapy of bladder urothelial carcinoma. \n \n \nKey words: \nUrinary bladder neoplasms; Neoadjuvant chemotherapy; Sensitivity; Markers","PeriodicalId":10343,"journal":{"name":"中华泌尿外科杂志","volume":"41 1","pages":"68-71"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progress in research of sensitive markers to neoadjuvant chemotherapy in muscle invasive bladder cancer\",\"authors\":\"Zhilong Hu, Hongsong Bai\",\"doi\":\"10.3760/CMA.J.ISSN.1000-6702.2020.01.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bladder cancer is one of the tenth most common malignant tumors in Chinese men. Almost 20% to 30% patients are diagnosed as the muscle-invasive bladder cancer (MIBC) at the first diagnosis.In the past, radical cystectomy (RC) was the first-line treatment with MIBC.The current researches' results show that, neoadjuvant chemotherapy combined with RC can improve the tumor complete response rate and prolong the overall survival of patients with MIBC, comparing with the RC alone. It has become the recommended standard first line treatment for MIBC, which has the possiblity of preserving bladder. Lots of researches indicate that the application of cisplatin-based neoadjuvant chemotherapy in patients with MIBC is becoming more and more popular. However, there is still the possibility of ineffectiveness or tumor progression. Therefore, discussions about the sensitivity of neoadjuvant chemotherapy have always been a hot spot in urological tumor research. In order to provide guidance and help for clinical work, the article reviews the sensitivity of neoadjuvant chemotherapy of bladder urothelial carcinoma. \\n \\n \\nKey words: \\nUrinary bladder neoplasms; Neoadjuvant chemotherapy; Sensitivity; Markers\",\"PeriodicalId\":10343,\"journal\":{\"name\":\"中华泌尿外科杂志\",\"volume\":\"41 1\",\"pages\":\"68-71\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华泌尿外科杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1000-6702.2020.01.017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华泌尿外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1000-6702.2020.01.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

癌症是中国男性第十大恶性肿瘤之一。几乎20%至30%的患者在首次诊断时被诊断为肌肉浸润性癌症（MIBC）。在过去，根治性膀胱切除术（RC）是MIBC的一线治疗方法。目前的研究结果表明，与单纯RC相比，新辅助化疗联合RC可以提高MIBC患者的肿瘤完全缓解率，延长患者的总生存期。它已成为MIBC的推荐标准一线治疗方法，有可能保留膀胱。大量研究表明，以顺铂为基础的新辅助化疗在MIBC患者中的应用越来越普遍。然而，仍然存在无效或肿瘤进展的可能性。因此，关于新辅助化疗敏感性的讨论一直是泌尿外科肿瘤研究的热点。本文就膀胱尿路上皮癌新辅助化疗的敏感性进行综述，以期对临床工作提供指导和帮助。关键词：膀胱肿瘤；新辅助化疗；敏感性；标记

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Progress in research of sensitive markers to neoadjuvant chemotherapy in muscle invasive bladder cancer

Bladder cancer is one of the tenth most common malignant tumors in Chinese men. Almost 20% to 30% patients are diagnosed as the muscle-invasive bladder cancer (MIBC) at the first diagnosis.In the past, radical cystectomy (RC) was the first-line treatment with MIBC.The current researches' results show that, neoadjuvant chemotherapy combined with RC can improve the tumor complete response rate and prolong the overall survival of patients with MIBC, comparing with the RC alone. It has become the recommended standard first line treatment for MIBC, which has the possiblity of preserving bladder. Lots of researches indicate that the application of cisplatin-based neoadjuvant chemotherapy in patients with MIBC is becoming more and more popular. However, there is still the possibility of ineffectiveness or tumor progression. Therefore, discussions about the sensitivity of neoadjuvant chemotherapy have always been a hot spot in urological tumor research. In order to provide guidance and help for clinical work, the article reviews the sensitivity of neoadjuvant chemotherapy of bladder urothelial carcinoma. Key words: Urinary bladder neoplasms; Neoadjuvant chemotherapy; Sensitivity; Markers

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华泌尿外科杂志 Medicine-Nephrology

CiteScore

0.10

自引率

0.00%

发文量

14180

期刊介绍： Chinese Journal of Urology (monthly) was founded in 1980. It is a publicly issued academic journal supervised by the China Association for Science and Technology and sponsored by the Chinese Medical Association. It mainly publishes original research papers, reviews and comments in this field. This journal mainly reports on the latest scientific research results and clinical diagnosis and treatment experience in the professional field of urology at home and abroad, as well as basic theoretical research results closely related to clinical practice. The journal has columns such as treatises, abstracts of treatises, experimental studies, case reports, experience exchanges, reviews, reviews, lectures, etc. Chinese Journal of Urology has been included in well-known databases such as Peking University Journal (Chinese Journal of Humanities and Social Sciences), CSCD Chinese Science Citation Database Source Journal (including extended version), and also included in American Chemical Abstracts (CA). The journal has been rated as a quality journal by the Association for Science and Technology and as an excellent journal by the Chinese Medical Association.